According to the Zhitong Finance APP, Huakang Biomed (08622) announced its mid-year results for 2024, with revenue increasing by about 4% year-on-year to 11.9 million yuan. The company's shareholders should have a loss of about 1.779 million yuan, a YOY expansion of 22.27%; basic loss per share is 0.38 points.

The announcement stated that the increase in revenue was mainly due to the sales increase in the group's biological preparations during the reporting period. The increase in losses was mainly due to the increase in R&D expenses during the reporting period.